Evidence map›Paper›PMID 36555526›Full record

ArticleInternational journal of molecular sciences2022

The Genetic Diversity and Dysfunctionality of Catalase Associated with a Worse Outcome in Crohn's Disease.

Marisa Iborra, Inés Moret, Enrique Busó, José Luis García-Giménez, Elena Ricart, Javier P Gisbert, Eduard Cabré, Maria Esteve, Lucía Márquez-Mosquera, Esther García-Planella and 7 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Marisa IborraGastroenterology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.
Inés MoretMedical Research Institute Hospital La Fe (IIS La Fe), 46026 Valencia, Spain.ORCID 0000-0003-2086-1521
Enrique BusóCentral Unit for Research in Medicine (UCIM), Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain.
José Luis García-GiménezINCLIVA Biomedical Research Institute, Spanish Institute of Health Carlos III, Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Center for Biomedical Research Network on Rare Diseases (CIBERER), 46010 Valencia, Spain.ORCID 0000-0001-7547-7872
Elena RicartInflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clìnic de Barcelona, CIBEREHD, IDIBAPS, 08036 Barcelona, Spain.
Javier P GisbertGastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), CIBEREHD, 28006 Madrid, Spain.ORCID 0000-0003-2090-3445
Eduard CabréGastroenterology Department, Hospital Germans Trias i Pujol, CIBEREHD, 08916 Badalona, Spain.
Maria EsteveGastroenterology Department, Hospital Universitari Mutua de Terrassa, CIBEREHD, 08221 Barcelona, Spain.ORCID 0000-0001-7716-0027
Lucía Márquez-MosqueraServei de Digestiu, Hospital del Mar, Barcelona, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.ORCID 0000-0002-3182-9570
Esther García-PlanellaGastroenterology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
Jordi GuardiolaGastroenterology Department, Hospital Universitari de Bellvitge, Hospital de Llobregat-Barcelona, 08901 Barcelona, Spain.
Federico V PallardóINCLIVA Biomedical Research Institute, Spanish Institute of Health Carlos III, Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Center for Biomedical Research Network on Rare Diseases (CIBERER), 46010 Valencia, Spain.ORCID 0000-0003-3715-1980
Carolina SerenaInstitut d'Investigació Sanitària Pere Virgili, Hospital Universitari Joan XXIII, 43007 Tarragona, Spain.ORCID 0000-0003-2251-0856
Francisco Algaba-ChuecaMedicine and Surgery Department, University Rovira i Virgili, 43201 Reus, Spain.ORCID 0000-0002-6537-1502
Eugeni DomenechGastroenterology Department, Hospital Germans Trias i Pujol, CIBEREHD, 08916 Badalona, Spain.ORCID 0000-0002-2315-7196
Pilar NosGastroenterology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.ORCID 0000-0002-6619-1511
Belén BeltránHospital Vithas Virgen del Consuelo, 46007 Valencia, Spain.ORCID 0000-0002-7063-6376
Universitat de València · ESCentro de Investigación Biomédica en Red · ESHospital Universitari Germans Trias i Pujol · ESHospital Universitari i Politècnic La Fe · ESBellvitge University Hospital · ESHospital Del Mar · ESHospital de Sant Pau · ESInstitut de Recerca Biomèdica Catalunya Sud · ESInstituto de Investigación Sanitaria La Fe · ESMútua Terrassa · ESUniversitat Rovira i Virgili · ES

Funding

Instituto de Salud Carlos III CM07/00133Instituto de Salud Carlos III PI14/01702.
6 · The paper itself

Abstract

Chronic gut inflammation in Crohn’s disease (CD) is associated with an increase in oxidative stress and an imbalance of antioxidant enzymes. We have previously shown that catalase (CAT) activity is permanently inhibited by CD. The purpose of the study was to determine whether there is any relationship between the single nucleotide polymorphisms (SNPs) in the CAT enzyme and the potential risk of CD associated with high levels of oxidative stress. Additionally, we used protein and regulation analyses to determine what causes long-term CAT inhibition in peripheral white mononuclear cells (PWMCs) in both active and inactive CD. We first used a retrospective cohort of 598 patients with CD and 625 age-matched healthy controls (ENEIDA registry) for the genotype analysis. A second human cohort was used to study the functional and regulatory mechanisms of CAT in CD. We isolated PWMCs from CD patients at the onset of the disease (naïve CD patients). In the genotype-association SNP analysis, the CAT SNPs rs1001179, rs475043, and rs525938 showed a significant association with CD (p < 0.001). Smoking CD patients with the CAT SNP rs475043 A/G genotype had significantly more often penetrating disease (p = 0.009). The gene expression and protein levels of CAT were permanently reduced in the active and inactive CD patients. The inhibition of CAT activity in the PWMCs of the CD patients was related to a low concentration of CAT protein caused by the downregulation of CAT-gene transcription. Our study suggests an association between CAT SNPs and the risk of CD that may explain permanent CAT inhibition in CD patients together with low CAT gene and protein expression.

Indexed as

Crohn DiseaseAntioxidantsCase-Control StudiesCatalaseGenetic Predisposition to DiseaseGenetic VariationGenotypeHumansInflammationPolymorphism, Single NucleotideRetrospective StudiesAntioxidantsCatalaseantioxidant genescatalaseCrohn’s diseaseinflammatory bowel diseaseoxidative stress

Identifiers

PMID36555526
PMCPMC9785615
OpenAlexW4311376544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.